Related Experiment Video
Updated: Jun 11, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
The FIMP Medicines for Children Research Network
Ettore Napoleone1, Giuseppe Mele
1Indirizzo: Piazza della Vittoria 14/A, Campobasso 86100, Italia. ettorenapoleone@tiscali.it
Italian Journal of Pediatrics
|July 2, 2010
Summary
The European Paediatric Regulation mandates ethical research and medicinal products for children. The Family Paediatricians Medicines for Children Research Network (FIMP-MCRN) has significantly improved paediatric clinical trials through infrastructure and training.
Area of Science:
- Pediatric Pharmacology
- Clinical Trial Management
- Regulatory Science
Background:
- The European Paediatric Regulation (EUPR) mandates ethical research and data generation for pediatric medicinal products, including off-label and unlicensed uses.
- Paediatric clinical trials are essential for ensuring the safety and efficacy of drugs in children.
- The establishment of the Family Paediatricians Medicines for Children Research Network (FIMP-MCRN) in 2003 aimed to build capacity for pediatric clinical trials.
Discussion:
- The FIMP-MCRN, comprising twenty Paediatric Regional Networks, has demonstrated substantial progress in enhancing the conduct of paediatric clinical trials.
- The network has successfully developed competence, infrastructure, networking, and educational frameworks for pediatric research.
- Ad hoc training programs have effectively increased knowledge among Family Paediatrician Investigators (FPI) regarding clinical trials.
Key Insights:
- The FIMP-MCRN has achieved valuable improvements in the execution of paediatric clinical trials.
- Training initiatives have successfully raised awareness among medical professionals and the public about the importance and benefits of pediatric trials.
- The network's development signifies a commitment to advancing pediatric medicine through rigorous research.
Outlook:
- Continued expansion and refinement of the FIMP-MCRN infrastructure and training programs are anticipated.
- Further integration of research findings into clinical practice is expected to enhance child health outcomes.
- Sustained collaboration and education will be crucial for addressing future challenges in pediatric drug development.
Related Concept Videos
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:02Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...